Kinases provide tractable targets for pharmacological inhibition and a number of PKC inhibitors have advanced in clinical trials for a number of diseases, including oncology, congestive heart failure, bipolar disorder, and diabetic retinopathy [55]. Here, PRRT2 is linked to bipolar disorder.